We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

Collaboration in the race to find a Covid-19 vaccine

Intellectual Property Magazine

Collaboration in the race to find a Covid-19 vaccine

Tania Shapiro-Barr says in order to mitigate the IP risks during collaboration over Covid-19 vaccine developments, a balance must be struck between sharing and protecting IP

As the world eagerly awaits the introduction of a vaccine for Covid-19, all eyes are on the life sciences industry.  More than ever before, biopharmaceutical scientists and researchers are working together to fight the pandemic. This collaboration is key to the rapid development of a safe and effective vaccine. In order for open collaboration and sharing of intellectual property to continue in the life sciences arena, however, it must operate within the existing legal framework for IP protection.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?


Request a trial Find out more